93 related articles for article (PubMed ID: 26647895)
1. [Immunoscore and Its Predictive Value for Colorectal Cancer].
Závadová E; Špaček J; Vočka M; Konopásek B; Fučíková T; Netíková I; Dundr P; Skálová H; Petruželka L
Klin Onkol; 2015; 28 Suppl 4():4S82-5. PubMed ID: 26647895
[TBL] [Abstract][Full Text] [Related]
2. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Immunoscore in Colorectal Carcinomas.
Imen H; Amira H; Fatma K; Raja J; Mariem S; Haithem Z; Ehsene BB; Aschraf C
Int J Surg Pathol; 2024 Feb; 32(1):58-65. PubMed ID: 37097904
[No Abstract] [Full Text] [Related]
4. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Bruni D; Angell HK; Galon J
Nat Rev Cancer; 2020 Nov; 20(11):662-680. PubMed ID: 32753728
[TBL] [Abstract][Full Text] [Related]
5. An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis.
Zhao Y; Chen C; Xu X; Ge X; Ding K; Zheng S; Wang J; Sun L
Oncoimmunology; 2021 Mar; 10(1):1901464. PubMed ID: 33796414
[TBL] [Abstract][Full Text] [Related]
6. Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients.
Baldin P; Van den Eynde M; Mlecnik B; Galon J
Oncoimmunology; 2020 Oct; 9(1):1826133. PubMed ID: 33110705
[TBL] [Abstract][Full Text] [Related]
7. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.
Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Vliet SVL; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672367
[TBL] [Abstract][Full Text] [Related]
8. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.
Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Marincola FM; Ascierto PA; Fox BA; Pagès F; Kawakami Y; Galon J
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139506
[TBL] [Abstract][Full Text] [Related]
9. CD8-positive T Cell Infiltration With Human Leukocyte Antigen Class 1 Expression Predicts Patients With Stage IV Colorectal Cancer Survival.
Satoyoshi T; Hirohashi Y; Okuya K; Miyo M; Akizuki E; Ishii M; Miura R; Kubo T; Murata K; Kanaseki T; Tsukahara T; Takemasa I; Torigoe T
Anticancer Res; 2024 Apr; 44(4):1603-1610. PubMed ID: 38537969
[TBL] [Abstract][Full Text] [Related]
10. Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients.
Wang Y; Dong J; Quan Q; Liu S; Chen X; Cai X; Qiu H; Zhang B; Guo G
Front Oncol; 2020; 10():581051. PubMed ID: 33585196
[TBL] [Abstract][Full Text] [Related]
11. Immune scores in colorectal cancer: Where are we?
Malka D; Lièvre A; André T; Taïeb J; Ducreux M; Bibeau F
Eur J Cancer; 2020 Nov; 140():105-118. PubMed ID: 33075623
[TBL] [Abstract][Full Text] [Related]
12. The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.
Lanzi A; Sinicrope FA; Benson AB; Galon J
Oncoimmunology; 2020 Jul; 9(1):1796003. PubMed ID: 32934890
[TBL] [Abstract][Full Text] [Related]
13. Usefulness and robustness of Immunoscore for personalized management of cancer patients.
Marliot F; Pagès F; Galon J
Oncoimmunology; 2020 Oct; 9(1):1832324. PubMed ID: 33194318
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer.
Wang F; Lu S; Cao D; Qian J; Li C; Zhang R; Wang F; Wu M; Liu Y; Pan Z; Wu X; Lu Z; Ding P; Li L; Lin J; Catteau A; Galon J; Chen G
Oncoimmunology; 2023; 12(1):2161167. PubMed ID: 36632564
[TBL] [Abstract][Full Text] [Related]
15. Multiverse of immune microenvironment in metastatic colorectal cancer.
Van den Eynde M; Mlecnik B; Bindea G; Galon J
Oncoimmunology; 2020 Sep; 9(1):1824316. PubMed ID: 33457100
[TBL] [Abstract][Full Text] [Related]
16. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions.
Pagès F; Taieb J; Laurent-Puig P; Galon J
Oncoimmunology; 2020 Aug; 9(1):1812221. PubMed ID: 32939329
[TBL] [Abstract][Full Text] [Related]
17. The consensus immunoscore: toward a new classification of colorectal cancer.
Lanzi A; Pagès F; Lagorce-Pagès C; Galon J
Oncoimmunology; 2020 Jul; 9(1):1789032. PubMed ID: 32934885
[TBL] [Abstract][Full Text] [Related]
18. Metastasis immune-based scores predict patient survival.
Mlecnik B; Bindea G; Van den Eynde M; Galon J
Oncoimmunology; 2020 Aug; 9(1):1806000. PubMed ID: 32923167
[TBL] [Abstract][Full Text] [Related]
19. The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.
Wozniakova M; Skarda J; Raska M
Pathol Oncol Res; 2022; 28():1610502. PubMed ID: 35936516
[TBL] [Abstract][Full Text] [Related]
20. Tumor spread or siege immunity: dissemination to distant metastasis or not.
Bindea G; Mlecnik B; Galon J
Oncoimmunology; 2021 Apr; 10(1):1919377. PubMed ID: 33996269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
